Tuesday, March 17, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Germany sees Covid-19 spike as EU-wide vaccinations fall short of 70% target

German Chancellor Angela Merkel warned on Thursday that new cases of Covid-19 in her country were rising “exponentially”, driven by the Delta variant, as EU officials said more than half of all European adults had been fully vaccinated, short of a 70% target set for the summer.

The EU said the number of fully vaccinated Europeans had passed the 200-million mark, more than half of the adult population but still short of a 70% target set for the end of July.

The fresh data came as Merkel urged more Germans to get jabs, sounding the alarm over a fresh spike in Covid-19 cases in Germany.

“We are seeing exponential growth,” she told a news conference in Berlin, adding that “every vaccination … is a small step towards a return to normality”.

Germany has seen an incidence rate of 12.2 new cases per 100,000 people over the past seven days – more than double rates in early July.

“With a rising incidence rate, it could be that we need to introduce additional measures,” she said.

Germany joins a number of European nations that have seen cases climb in recent weeks fuelled by the Delta variant, first detected in India.

The European Central Bank said uncertainty over the wave of infections meant it was keeping the cash taps open to ensure the nascent economic recovery isn’t snuffed out.

ECB chief Christine Lagarde said the bank would keep its vast stimulus for the eurozone firmly in place following a meeting of its 25-member governing council.

“The euro area economy is rebounding strongly,” Lagarde said, but the Delta variant could damp the post-lockdown recovery “in services, especially in tourism and hospitality”, she said.

Source: France 24

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!